JP2022500392A5 - - Google Patents

Info

Publication number
JP2022500392A5
JP2022500392A5 JP2021513407A JP2021513407A JP2022500392A5 JP 2022500392 A5 JP2022500392 A5 JP 2022500392A5 JP 2021513407 A JP2021513407 A JP 2021513407A JP 2021513407 A JP2021513407 A JP 2021513407A JP 2022500392 A5 JP2022500392 A5 JP 2022500392A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
solvate
acceptable salt
compound according
Prior art date
Application number
JP2021513407A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020061113A5 (https=
JP2022500392A (ja
JP7554739B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/051603 external-priority patent/WO2020061113A1/en
Publication of JP2022500392A publication Critical patent/JP2022500392A/ja
Publication of JPWO2020061113A5 publication Critical patent/JPWO2020061113A5/ja
Publication of JP2022500392A5 publication Critical patent/JP2022500392A5/ja
Application granted granted Critical
Publication of JP7554739B2 publication Critical patent/JP7554739B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021513407A 2018-09-18 2019-09-17 ファルネソイドx受容体アゴニストおよびその使用 Active JP7554739B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862733004P 2018-09-18 2018-09-18
US201862733006P 2018-09-18 2018-09-18
US62/733,006 2018-09-18
US62/733,004 2018-09-18
US201962881560P 2019-08-01 2019-08-01
US62/881,560 2019-08-01
PCT/US2019/051603 WO2020061113A1 (en) 2018-09-18 2019-09-17 Farnesoid x receptor agonists and uses thereof

Publications (4)

Publication Number Publication Date
JP2022500392A JP2022500392A (ja) 2022-01-04
JPWO2020061113A5 JPWO2020061113A5 (https=) 2022-09-27
JP2022500392A5 true JP2022500392A5 (https=) 2022-09-27
JP7554739B2 JP7554739B2 (ja) 2024-09-20

Family

ID=69887982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021513407A Active JP7554739B2 (ja) 2018-09-18 2019-09-17 ファルネソイドx受容体アゴニストおよびその使用

Country Status (27)

Country Link
US (4) US11084817B2 (https=)
EP (2) EP4596543A3 (https=)
JP (1) JP7554739B2 (https=)
KR (2) KR102810978B1 (https=)
CN (1) CN113056271B (https=)
AU (2) AU2019344903B2 (https=)
BR (1) BR112021004919A2 (https=)
CA (1) CA3112411A1 (https=)
CL (1) CL2021000632A1 (https=)
DK (1) DK3852748T3 (https=)
ES (1) ES3051007T3 (https=)
FI (1) FI3852748T3 (https=)
HR (1) HRP20251321T1 (https=)
IL (1) IL281475B2 (https=)
LT (1) LT3852748T (https=)
MA (1) MA53665B1 (https=)
MD (1) MD3852748T2 (https=)
MX (1) MX2021003110A (https=)
PH (1) PH12021550605A1 (https=)
PL (1) PL3852748T3 (https=)
PT (1) PT3852748T (https=)
RS (1) RS67371B1 (https=)
SG (1) SG11202102651SA (https=)
SI (1) SI3852748T1 (https=)
SM (1) SMT202600076T1 (https=)
TW (1) TWI833805B (https=)
WO (1) WO2020061113A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7258763B2 (ja) * 2017-03-15 2023-04-17 メタクリン,インク. ファルネソイドx受容体アゴニストおよびその使用
CA3055990A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
AU2019344903B2 (en) 2018-09-18 2025-02-27 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof
IL293892A (en) 2020-01-15 2022-08-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Use of fxr agonists for treating an infection by hepatitis d virus
CN120732855A (zh) * 2020-03-18 2025-10-03 伊莱利利公司 用于治疗疾病的法尼醇x受体激动剂
WO2021188695A1 (en) 2020-03-18 2021-09-23 Metacrine, Inc. Formulations of a farnesoid x receptor agonist
KR20220155356A (ko) * 2020-03-18 2022-11-22 메타크린, 인크. 파르네소이드 x 수용체 효능제의 결정형
JP2024502673A (ja) 2021-01-14 2024-01-22 ウエヌイグレックオ・ファーマ Hbv感染の処置のためのfxrアゴニストとifnの相乗効果
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてfxrアゴニストを使用するtlr3アゴニストの効果の強い増強
CN116554121A (zh) * 2023-05-05 2023-08-08 济南悟通生物科技有限公司 一种2-异丁基噻唑的合成方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069810A1 (en) 1999-05-17 2000-11-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6645980B1 (en) 2000-05-25 2003-11-11 Sepracor Inc. Heterocyclic analgesic compounds and methods of use thereof
JP2003500392A (ja) 1999-05-25 2003-01-07 セプラコール, インク. 複素環式鎮痛性化合物およびその使用方法
US6511980B2 (en) 2000-05-05 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Substituted diamine derivatives useful as motilin antagonists
IL154363A0 (en) 2000-09-25 2003-09-17 Actelion Pharmaceuticals Ltd Substituted amino-aza-cycloalkanes useful against malaria
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
FR2825706B1 (fr) 2001-06-06 2003-12-12 Pf Medicament Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase
FR2839974B1 (fr) 2002-05-24 2004-07-16 Pf Medicament Derives de phenyl-furane ou de phenyl-thiophene,leur preparation et leur application a titre de medicament
AU2003249983A1 (en) 2002-07-18 2004-02-09 Actelion Pharmaceuticals Ltd Piperidines useful for the treatment of central nervous system disorders
BR0314126A (pt) 2002-09-20 2005-06-28 Pfizer Prod Inc Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio
WO2004046162A2 (en) 2002-11-14 2004-06-03 The Scripps Research Institute Non-steroidal fxr agonists
US20050143449A1 (en) 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
US7647217B2 (en) 2002-11-15 2010-01-12 The Salk Institute For Biological Studies Structure of the farnesoid X receptor ligand binding domain and methods of use therefor
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
US7754711B2 (en) 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
EP1648874B1 (en) 2003-07-30 2011-10-05 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
WO2005058822A1 (en) 2003-12-17 2005-06-30 Actelion Pharmaceuticals Ltd Substituted amino-cycloalkanes
WO2005097760A1 (en) 2004-03-26 2005-10-20 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
WO2005113522A1 (en) 2004-05-07 2005-12-01 Janssen Pharmaceutica, N.V. Azole carboxamide inhibitors of bacterial type iii protein secretion systems
JP2006199656A (ja) 2005-01-24 2006-08-03 Kowa Co アミド基を有する環状アミン化合物
MY144229A (en) 2006-01-26 2011-08-15 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use as therapeutic agents
EP2001851A2 (en) 2006-03-28 2008-12-17 Novartis AG Amide derivatives and their application for the treament of g protein related diseases
US20080081824A1 (en) 2006-09-29 2008-04-03 Bristol-Myers Squibb Company Substituted piperidines as modulators of chemokine receptor activity
WO2008065500A2 (en) 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
WO2010001869A1 (ja) 2008-06-30 2010-01-07 武田薬品工業株式会社 4置換ベンゼン化合物およびその用途
JP2010077109A (ja) 2008-08-28 2010-04-08 Takeda Chem Ind Ltd 複素環化合物およびその用途
EP2454243A2 (en) 2009-07-15 2012-05-23 Merck Serono SA Tetrazole derivatives
CA2767089A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
FR2963005B1 (fr) 2010-07-23 2012-08-17 Sanofi Aventis Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique
ME02754B (me) 2011-03-23 2018-01-20 Trevena Inc Ligandi opioidnih receptora i postupci njihove upotrebe i pripreme
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EP2732871A4 (en) 2011-07-13 2015-03-04 M Tech Co Ltd PROCESS FOR PRODUCING MICROPARTICLES WITH CONTROLLED CRYSTALLITE DIAMETER
RU2543485C2 (ru) 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
GB201316824D0 (en) 2013-09-23 2013-11-06 R & D Vernalis Ltd New Chemical Entities
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
EP3116851B1 (en) 2014-03-13 2023-07-26 Salk Institute for Biological Studies Analogs of fexaramine and methods of making and using
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
KR20160132111A (ko) 2014-03-13 2016-11-16 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 Fxr 작용제와 제조방법 및 용도
US20150258052A1 (en) 2014-03-13 2015-09-17 Salk Institute For Biological Studies Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue
US20180116993A1 (en) 2015-01-22 2018-05-03 Xiamen University Modulators of farnesoid x receptor and methods for the use thereof
AU2016233579A1 (en) 2015-03-13 2017-10-12 Salk Institute For Biological Studies Treating latent autoimmune diabetes of adults with farnesoid X receptor agonists to activate intestinal receptors
WO2017018751A1 (ko) 2015-07-24 2017-02-02 동국대학교 산학협력단 Blt 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물
US10626081B2 (en) 2015-09-16 2020-04-21 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
WO2017049177A1 (en) * 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
US10703712B2 (en) * 2015-09-16 2020-07-07 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
EP3350164A4 (en) 2015-09-16 2019-03-27 Metacrine, Inc. FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF
CN105477636B (zh) * 2015-10-16 2019-09-17 厦门大学 使用阿维菌素及其衍生物治疗代谢疾病的方法
CN107126419B (zh) 2016-02-26 2020-06-19 石药集团中诺药业(石家庄)有限公司 一种奥贝胆酸片剂及其制备方法
WO2017170182A1 (ja) 2016-03-31 2017-10-05 株式会社Adeka 感光性組成物及び新規化合物
WO2018170167A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
US20200131129A1 (en) 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
JP7258763B2 (ja) * 2017-03-15 2023-04-17 メタクリン,インク. ファルネソイドx受容体アゴニストおよびその使用
CA3055990A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2018170165A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CZ2017298A3 (cs) 2017-05-26 2018-12-05 Zentiva, K.S. Amorfní formy obeticholové kyseliny
WO2020060007A1 (ko) 2018-09-17 2020-03-26 엘지전자 주식회사 5g 이동통신에서 pdu 세션을 핸들링하는 방법 및 무선 기기
JP2022500393A (ja) 2018-09-18 2022-01-04 メタクリン,インク. ファルネソイドx受容体アゴニストおよびその使用
WO2020061116A1 (en) 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2020061118A1 (en) 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
EP3852749A4 (en) 2018-09-18 2022-08-24 Metacrine, Inc. CRYSTALLINE FORMS OF A FARNESOID X RECEPTOR AGONIST
CN113056264A (zh) 2018-09-18 2021-06-29 梅塔科林公司 法尼醇x受体激动剂及其用途
AU2019344903B2 (en) 2018-09-18 2025-02-27 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof
EA202190661A1 (ru) 2018-09-18 2021-08-13 Метакрайн, Инк. Агонисты фарнезоидного х-рецептора для лечения заболевания
CN120732855A (zh) 2020-03-18 2025-10-03 伊莱利利公司 用于治疗疾病的法尼醇x受体激动剂
WO2021188695A1 (en) 2020-03-18 2021-09-23 Metacrine, Inc. Formulations of a farnesoid x receptor agonist
KR20220155356A (ko) 2020-03-18 2022-11-22 메타크린, 인크. 파르네소이드 x 수용체 효능제의 결정형

Similar Documents

Publication Publication Date Title
JP2022500392A5 (https=)
JP2020514333A5 (https=)
JP2014524472A5 (https=)
JP2020531418A5 (https=)
ES2546063T3 (es) Agentes de enlace a amiloides
JP2009084270A5 (https=)
ES2659739T3 (es) 3-acilatos III de ingenol y 3-carbamatos de ingenol
JP2021534124A5 (https=)
JP2010512342A5 (https=)
JP2011523412A5 (https=)
JP2021527638A5 (https=)
JP2011016849A5 (https=)
RU2016137832A (ru) Соединения для лечения опосредованных комплементом нарушений
JP2014511891A5 (https=)
RU2015105262A (ru) Азотсодержащие гетероциклические производные и их применение в фармацевтических препаратах
JP2017512186A5 (https=)
JP2016530209A5 (https=)
JP2006515838A5 (https=)
JP2009530424A5 (https=)
JP2020529994A5 (https=)
JP2010501584A5 (https=)
RU2011129856A (ru) Схема приема агониста рецептора s1p
JP2015508068A5 (https=)
JP2015519322A5 (https=)
JP2007517895A5 (https=)